Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles (168)

This study has been completed.
Sponsor:
Collaborator:
Dr. Loges & Co. GmbH
Information provided by (Responsible Party):
Pascoe Pharmazeutische Praeparate GmbH
ClinicalTrials.gov Identifier:
NCT00921934
First received: June 16, 2009
Last updated: September 25, 2012
Last verified: August 2012

June 16, 2009
September 25, 2012
April 2009
December 2010   (final data collection date for primary outcome measure)
Change of Pain Measured by VAS [ Time Frame: visit 1 - 3 ] [ Designated as safety issue: No ]
VAS (minimum = 0 = no pain, maximum = 10 = extrem pain, change of pain measured by VAS
Not Provided
Complete list of historical versions of study NCT00921934 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
PASCORBIN 7.5g in the Treatment of Viral Infection, Especially Varicella Zoster Infection: An Observational Cohort Study

Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases.

Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Cohort of adult patients suffering from acute viral infections, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany.

  • Virus Diseases
  • Herpes Zoster
Not Provided
Vitamin C
Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
December 2010
December 2010   (final data collection date for primary outcome measure)

Due to the design of an Observational Cohort Study, no inclusion or exclusion criteria are named. The included patient group is described under "Cohort / Group".

Observational Criteria:

  • adult patients
  • acute viral infection (especially herpes zoster)
  • Primary Care patient
  • eligible for add-on therapy with vitamin C
  • willingness to provide pseudonymized data to the Sponsor
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00921934
168 A 08 VC
No
Pascoe Pharmazeutische Praeparate GmbH
Pascoe Pharmazeutische Praeparate GmbH
Dr. Loges & Co. GmbH
Principal Investigator: Martin Schencking, MD Rheinstr. 77a, D-56235 Ransbach-Baumbach
Study Director: Bianka Krick Pascoe Pharmazeutische Praeparate GmbH
Pascoe Pharmazeutische Praeparate GmbH
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP